PTCTPTC THERAPEUTICS, INC.
Pharmaceutical Preparations
- Revenue
- $1.7B
- 115% YoY
- Operating margin
- 50.1%
- 234% YoY
- EBITDA
- $906M
- 499% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -0.5×
- −$416M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear104% of net incomeCash flow under 80% of net income
- Dilutive SBCClear4% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear3% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $539M | $699M | $938M | $807M | $1.7B | 115% |
| Operating income | −$374M | −$447M | −$440M | −$303M | $867M | 387% |
| Net income | −$524M | −$559M | −$627M | −$363M | $683M | 288% |
| Operating cash flow | −$251M | −$357M | −$158M | −$108M | $711M | 760% |
| Capex | $28M | $32M | $28M | $7M | $9M | 36% |
| Stock-based comp | $104M | $110M | $102M | $75M | $75M | 0.1% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $6M · 19
- Net
- −$6M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 125 | 120 |
| FY2024 | — | — | 74 | 91 |
| FY2023 | — | — | 45 | 92 |
| FY2022 | — | — | 63 | 89 |
| FY2021 | — | — | 65 | 99 |